• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • Patient Education
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Directories » FDA Approved Drugs » Aredia (pamidronate disodium for injection)

AND
  • A
  • B
  • C
  • D
  • E
  • F
  • G
  • H
  • I
  • J
  • K
  • L
  • M
  • N
  • O
  • P
  • Q
  • R
  • S
  • T
  • U
  • V
  • W
  • X
  • Y
  • Z

Aredia (pamidronate disodium for injection)

  • Profile

Profile

Contact Information

Currently Enrolling Trials

    Show More

    General Information

    Aredia has been approved for treatment of osteolytic bone metastases of breast cancer, in conjunction with standard antineoplastic therapy. Aredia is the first drug that has been proven to reduce the incidence of skeletal complications of metastatic breast cancer, thereby reducing the need for radiation therapy or surgery to the bone. It has also been shown to provide relief of bone pain caused by metastatic breast cancer, thereby reducing the need for narcotic analgesics. The drug is also indicated for the treatment of osteolytic bone lesions of multiple myeloma, moderate-to-severe hypercalcemia of malignancy, and moderate-to-severe Paget's disease.

    Clinical Results

    The marketing clearance was based upon data from two large, placebo-controlled, double-blind, multicenter studies in breast cancer subjects with osteolytic bone metastases. These studies enrolled 372 subjects treated with hormonal therapy and 382 subjects treated with chemotherapy. All subjects enrolled had stage IV breast cancer with two or more lytic lesions, with at least one lesion that was one centimeter or greater in diameter. Subjects were randomized to receive Aredia 90 mg every three to four weeks via two-hour IV infusions for 12 months or matching placebo, in conjunction with either hormonal therapy or chemotherapy. The studies demonstrated that patients receiving Aredia had a significant reduction in skeletal complications, the primary endpoint, and significant relief of bone pain, a secondary endpoint. The Aredia treatment effect appeared to be less pronounced in the study of those receiving chemotherapy. Additionally, subjects receiving Aredia had fewer pathologic fractures and a decreased need for radiation therapy for pain or skeletal complications.

    In these studies, skeletal morbidity was defined as the mean number of skeletal complications (pathologic fractures, spinal cord compression, radiation therapy, or surgery to bone) per subject per year. In subjects receiving concomitant chemotherapy, Aredia provided a 36% reduction in the skeletal morbidity rate (2.1 vs. 3.3 with placebo). In subjects receiving concomitant hormonal therapy, skeletal morbidity was reduced by 31% with Aredia (2.4 vs. 3.5). For an average subject, these reductions mean one fewer major skeletal complication per year with Aredia.

    Additional results of the trials show that subjects treated with Aredia had fewer skeletal complications than those subjects who received placebo. Also, fewer Aredia-treated subjects required radiation therapy for pain, or to prevent or treat fractures, compared to subjects treated with placebo. Among subjects who had pain at the beginning of the trials, Ardia-treated subjects had less severe pain, and experienced pain less often, in comparison to subjects who did not receive Aredia. Additionally, Aredia-treated subjects also had a decreased need for strong pain medication, unlike subjects receiving placebo. The statistical significance of these results may be overstated due to numerous analyses.

    Side Effects

    The incidence and type of adverse events with Aredia were similar to those with placebo, with most events likely due to the underlying disease or concomitant antineoplastic therapy. The most frequent adverse events were fatigue, fever, nausea, vomiting, anemia, and skeletal pain. Transient arthralgias and myalgias were reported slightly more frequently with Aredia than with antineoplastic therapy alone (12% and 23% vs. 8% and 17%, respectively). Serum calcium and electrolytes must be closely monitored, as must subjects with preexisting anemia, leukopenia, or thrombocytopenia.

    Additional Information

    Breast cancer is diagnosed in approximately 184,000 women each year, and has the highest incidence of associated metastatic bone disease among all cancers. Approximately 100,000 breast cancer subjects are currently living with cancer that has metastasized to the bone. Subjects with osteolytic bone metastases often suffer from skeletal complications including pathologic bone fractures, spinal cord compression, impaired mobility, and chronic and debilitating bone pain.

    Approval Date: 1996-08-01
    Company Name: Chiron
    Back to Listings

    Upcoming Events

    • 27Jan

      Medical Device Clinical Trials in China: Latest Regulatory Developments

    • 11Feb

      Lab X.0: Addressing Quality and Compliance Challenges in Laboratory Operations in the COVID-19 All-Digital Era

    • 23Mar

      Data Integrity for GCP Professionals: Core Requirements, Expectations and Challenges

    • 26Apr

      MAGI's Clinical Research vConference — Spring 2021

    Featured Products

    • Regenerative Medicine – Steps to Accelerate Development : PDF

      Regenerative Medicine: Steps to Accelerate Development

    • Clinical Trial Agreements — A Guide to Key Words and Phrases : PDF

      Clinical Trial Agreements: A Guide to Key Words and Phrases

    Featured Stories

    • Resources-360x240.png

      Trial Complexity, Endpoints Continue to Increase, Stretching Site Resources

    • FocusinRed-360x240.png

      Return to Focus on Risk Management Postpandemic Could Prove Challenging to Sites

    • VaccinewithNeedle-360x240.png

      2021 Vaccine Industry Will Continue to be Dominated by COVID-19 Trials, Experts Say

    • Dominate-360x240.png

      COVID-19, Oncology, CNS and Infectious Disease Trials Will Dominate in 2021, Survey Predicts

    Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

    The information you need to adapt your monitoring plan to changing times.

    Learn More Here
    • About Us
    • Contact Us
    • Privacy Policy
    • Do Not Sell My Personal Information

    Footer Logo

    300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

    Phone 617.948.5100 – Toll free 866.219.3440

    Copyright © 2021. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing